Fig. 5

Metachronous RC and immunological response (IMMUNOREACT 9: therapy naïve patients). Representative immunohistochemical analysis of CD80, and PDL-1 + leukocytes within the cancerization field, (20x bar = 0.050 mm). Representative immunohistochemical analysis of PMS2, and MSH6 within the cancerization field, (20x bar = 0.050 mm).